Facial Angiofibroma Severity Index (FASI): reliability assessment of a new tool developed to measure severity and responsiveness to therapy in tuberous sclerosis-associated facial angiofibroma

Summary Background Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous disorder characterized by the development of multisystem hamartomatous tumours. Topical sirolimus has recently been suggested as a potential treatment for TSC‐associated facial angiofibroma (FA). Aim To valid...

Full description

Bibliographic Details

Published in:	Clinical and experimental dermatology Vol. 39; no. 8; pp. 888 - 893
Main Authors:	Salido-Vallejo, R., Ruano, J., Garnacho-Saucedo, G., Godoy-Gijón, E., Llorca, D., Gómez-Fernández, C., Moreno-Giménez, J. C.
Format:	Journal Article
Language:	English
Published:	England Blackwell Publishing Ltd 01-12-2014 Oxford University Press
Subjects:	Angiofibroma - drug therapy Angiofibroma - etiology Angiofibroma - pathology Antibiotics, Antineoplastic - therapeutic use Facial Neoplasms - drug therapy Facial Neoplasms - etiology Facial Neoplasms - pathology Humans Immunosuppressive Agents - therapeutic use Observer Variation Reproducibility of Results Severity of Illness Index Sirolimus - therapeutic use Tuberous Sclerosis - complications
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!